ASH 2022 | FrontMIND: tafasitamab + lenalidomide + R-CHOP vs R-CHOP for newly diagnosed high-risk DLBCL
Umberto Vitolo
• 12 Dec 2022
Umberto Vitolo, MD, Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy, comments on the rationale and design of the frontMIND Phase III randomized trial (NCT04824092) assessing tafasitamab, lenalidomide and R-CHOP versus R-CHOP alone for newly diagnosed high-risk diffuse large B-cell lymphoma (DLBCL). This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Seagen, Genmab, Incyte, Costellation, Bayer, Regeneron: Consultancy; AbbVie, Incyte, Janssen, Gilead Sciences: Speakers Bureau.
